Faster FOLFOX: Oxaliplatin can be safely infused at a rate of 1 mg/m(2)/min Journal Article
| Authors: | Cercek, A.; Park, V.; Yaeger, R.; Reidy-Lagunes, D.; Kemeny, N. E.; Stadler, Z. K.; Segal, N. H.; Varghese, A.; Saltz, L. B. |
| Article Title: | Faster FOLFOX: Oxaliplatin can be safely infused at a rate of 1 mg/m(2)/min |
| Abstract: | Purpose Oxaliplatin at a dose of 85 mg/m2 traditionally has been administered over 120 min in the standard FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin) regimen. CapeOx (capecitabine plus oxaliplatin), in which the dose of oxaliplatin is 130 mg/m2, has also been infused over 120 min. Maintenance of a prolonged infusion time has been largely based on the concern for a potential hypersensitivity reaction (HSR) if administered too quickly. Methods We first performed a retrospective review of our institutional experience to assess whether HSR rates were similar in FOLFOX and CapeOx by using computerized pharmacy records between January 1, 2011, and December 31, 2013. We then instituted a new policy to infuse all nonresearch doses of oxaliplatin at a set rate of 1 mg/m2/min (85 mg/m2 given over 85min;68mg/m2 over68 min, etc). The incidence ofHSRswith thenewinfusion rate was actively monitored. Results Of 2,097 patients who previously received oxaliplatin over 120 min, 1,936 received a dose of 85 mg/m2 (±10%), and 161 received a dose of 130 mg/m2. The incidence of HSRs in the 85 mg/m2 group was 11% versus 7% in the 130 mg/m2 group (P =.13). Then between December 1,2014,andJune4,2015,667patientsreceived oxaliplatinatarate of1mg/m2/min for all doses. The incidence of HSRs in patients treated at this fixed infusion rate was 8%. Conclusion Infusing oxaliplatin at a rate of 1 mg/m2/min does not increase the rate of HSRs and does not compromise patient safety. This infusion rate is safe for use in routine practice. © 2016 by American Society of Clinical Oncology. |
| Journal Title: | Journal of Oncology Practice |
| Volume: | 12 |
| Issue: | 5 |
| ISSN: | 1554-7477 |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-01 |
| Start Page: | e548 |
| End Page: | e553 |
| Language: | English |
| DOI: | 10.1200/jop.2015.008417 |
| PROVIDER: | scopus |
| PUBMED: | 27072569 |
| PMCID: | PMC5702800 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 June 2016 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work